2024
Clinical and molecular characterization of urothelial (UC) vs. small cell carcinoma (SCC) of the urinary tract.
Chawla N, Mercier B, Govindarajan A, Li X, Castro D, Ebrahimi H, Barragan-Carrillo R, Zang P, LeVee A, Dizman N, Hsu J, Meza L, Zengin Z, Salgia N, Chehrazi-Raffle A, Dorff T, Pal S, Tripathi A. Clinical and molecular characterization of urothelial (UC) vs. small cell carcinoma (SCC) of the urinary tract. Journal Of Clinical Oncology 2024, 42: 682-682. DOI: 10.1200/jco.2024.42.4_suppl.682.Peer-Reviewed Original ResearchSmall cell carcinomaFeatures of small cell carcinomaGenome sequencePrevalence of genomic alterationsSmall cell carcinoma patientsSmall cell carcinoma groupFrequency of CDKN2APrevalence of TP53Fisher's exact testTumor gradeCell carcinomaPathological variablesUse of bloodUrinary tractBladder cancerExact testGenomic alterationsProportion Z testGenomic profilingGenomic featuresPathological featuresTherapeutic strategiesGenomic datasetsGenomic characteristicsBonferroni correction
2023
Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC).
Chehrazi-Raffle A, Tukachinsky H, Schrock A, Hwang J, Zengin Z, Meza L, Chawla N, Ebrahimi H, Govindarajan A, Castro D, Rock A, Tripathi A, Dorff T, Pal S, Oxnard G, Agarwal N, Antonarakis E. Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC). Journal Of Clinical Oncology 2023, 41: 220-220. DOI: 10.1200/jco.2023.41.6_suppl.220.Peer-Reviewed Original ResearchAdvanced prostate cancerComprehensive genomic profilingGenomic alterationsBRAF alterationsTissue biopsiesCancer typesFurther clinical investigationTMPRSS2-ERG fusionFoundationOne CDxMedian ageCommon genomic alterationsAPC patientsProstate cancerMolecular subtypesClinical investigationHigh incidenceActionable targetsBRAF rearrangementsCancer-related genesHotspot missense mutationsGenomic profilingBRAFCDK12 mutationsGenetic activationBiopsy